Context: WNT signaling is fundamental to bone health, and its aberrant activation leads to skeletal pathologies. The heterozygous missense mutation p.C218G in WNT1, a key WNT pathway ligand, leads to severe early-onset and progressive osteoporosis with multiple peripheral and spinal fractures. Despite the severe skeletal manifestations, conventional bone turnover markers are normal in mutation-positive patients.
B
one health is maintained by precisely balanced bone formation and resorption. In addition to key regulatory pathways and endocrine factors, microRNAs (miRNAs) have recently emerged as integral modulators of bone metabolism (1, 2) . miRNAs are short, noncoding RNA fragments that regulate target gene expression by posttranscriptional silencing or repression of protein translation and serve important functions in various biological processes (3) . In bone, miRNAs regulate both osteogenesis during fetal development and maintenance of bone health postnatally (3) (4) (5) (6) . In vitro studies further demonstrated their direct role in the regulation of osteoblast and osteoclast development, maturation, and function (7) (8) (9) (10) (11) . Furthermore, some clinical studies suggest that expression levels of different miRNAs are associated with idiopathic and postmenopausal osteoporosis, correlate with bone mineral density (BMD), and differentiate between patient cohorts (12) (13) (14) (15) (16) . On the basis of these observations, miRNAs are anticipated to have applications in the diagnosis and treatment of bone diseases, including osteoporosis (12, 16, 17) .
The canonical WNT/b-catenin pathway is a key regulator of bone metabolism, and defective WNT signaling underlies several monogenic skeletal disorders with low or high bone mass, such as osteoporosis-pseudoglioma syndrome, van Buchem disease, and sclerosteosis (18) (19) (20) . In 2013, our research group identified WNT1 as a major regulator of bone mass, as the heterozygous missense mutation p.C218G in WNT1 was shown to decrease activity of the WNT/b-catenin pathway in bone; this resulted in low bone turnover with a decreased number of bone cells and impaired bone formation and consequently low bone mass and skeletal fragility (21) . The mutation was first reported in a large Finnish family exhibiting severe earlyonset osteoporosis, multiple peripheral and spinal compression fractures, and subsequent loss in adult height (21, 22) . Despite the low BMD and major skeletal pathology, the conventional bone biomarkers currently in clinical use, such as alkaline phosphatase, the bone formation marker Nterminal propeptide of type I procollagen, and the bone resorption marker type I collagen cross-linked N-telopeptide, did not differ between WNT1 mutation-positive and mutation-negative individuals (21, 22) .
Recent in vitro studies showed that specific miRNAs regulate WNT signaling by binding to the pathway's key components and inhibitors: miR-152-3p and miR-335 to Dickkopf-1; miR-30e-5p to low-density lipoproteinreceptor 6; and miR-27a-3p, miR-142, and miR-135a to adenomatous polyposis coli (23) (24) (25) (26) (27) (28) . However, data on miRNA expression and circulating miRNA levels in genetic bone diseases are still scarce (29) . In patients with altered WNT signaling, the miRNA profiles, the potential roles of the miRNAs in disease pathogenesis, the clinical diagnostics, and the follow-up remain unknown and unexplored. To gain more insight into the clinical relevance of miRNAs in inherited bone diseases with defective WNT signaling, we assessed miRNA profiles in subjects with a heterozygous WNT1 mutation and their mutation-negative family members.
Subjects and Methods

Subjects
We previously identified two large Finnish families with autosomal dominant WNT1 osteoporosis (21, 22) . The first family (Family A) was identified in 2013 when the heterozygous missense mutation p.C218G in WNT1 was determined by linkage analysis and targeted sequencing to be the cause of severe early-onset osteoporosis in 10 affected family members (21) . We subsequently offered genetic screening to all first-degree relatives at risk, and, since then, 21 additional mutation-positive individuals in Family A have thus far been identified. When the whole WNT1 gene was Sanger sequenced for .250 other Finnish index patients with osteoporosis, a second family (Family B) was found to harbor the exact same point mutation. In this family, four subjects have so far been found to harbor the same mutation. Hence to date, altogether 25 mutation-positive subjects with the heterozygous p.C218G have been identified in Finland.
For the study, we offered all mutation-positive subjects from Family A and Family B (n 5 25) the opportunity to participate in research study concerning miRNAs in a search for new bone biomarkers associated with the heterozygous WNT1 mutation. A control group with similar age and sex distributions was formed by also offering the mutation-negative subjects in Family A (n = 29) and Family B (n = 3) the opportunity to participate. Altogether, 17 mutation-positive and 18 mutationnegative individuals consented.
All participants filled out a questionnaire with the following information: other diagnosed diseases, all previous fractures, all previous surgeries, previous bisphosphonate or other osteoporosis medication, other medications, and calcium and vitamin D supplementation. On the basis of these anamnestic data, we aimed to exclude subjects with fractures or orthopedic surgeries in the past 12 months or with possible confounding illnesses or medications.
Genetic evaluations
We screened all participating study subjects for the heterozygous missense mutation c.652T.G (p.C218G) in exon 4 of WNT1 (The National Center for Biotechnology Information Reference Sequence NM_005430.3). We performed genetic validations on DNA extracted from peripheral blood as previously described (22) .
Serum samples
We collected all serum samples during the spring season (January to April) in 2017 to avoid bias from variable sunlight exposure. All samples were taken after a 12-hour fast, in the morning between 0800 and 0900 hours. Venous blood was first collected into normal serum tubes and left to stand at room temperature for 30 to 60 minutes to allow clotting. The tubes were then centrifuged at 2500 3 g for 10 minutes at room temperature, and the supernatant was transferred to 1.5-mL tubes in 250-mL aliquots. The serum was immediately stored at 280°C until analysis.
Blood biochemistry
We assessed biochemical values from separate peripheral blood samples for serum calcium, phosphate, alkaline phosphatase, 25-hydroxyvitamin D (assessed with immunochemiluminometry), and 1,25-dihydroxyvitamin D (assessed with immunochemiluminometry). Results were compared with the laboratory's reference values. Serum parathyroid hormone and collagen type 1 crosslinked C-telopeptide (a bone resorption marker) were analyzed with an IDS-iSYS fully automated immunoassay system (Immunodiagnostic Systems, Ltd., Bolton, UK) with chemiluminescence detection and were compared with the manufacturer's reference values. Serum intact fibroblast growth factor 23 was assessed by manual enzyme-linked immunosorbent assay (Immutopics International, San Clemente, CA, and Kainos Laboratories, Tokyo, Japan); the manufacturers' reference values were used.
miRNA analysis
We isolated RNA from the serum samples using the miRNeasy Mini Kit (Qiagen, Hilden, Germany). Serum samples were thawed on ice and centrifuged at 12,000g for 5 minutes to remove any cellular debris. For each sample, 200 mL of serum was mixed with 1000 mL of Qiazol and 1 mL of synthetic spikeins (Exiqon, Vedbaek, Denmark). After a 10-minute incubation at room temperature, 200 mL of chloroform was added to the lysates followed by cooled centrifugation at 12,000g for 15 minutes at 4°C. Precisely 650 mL of the upper aqueous phase were mixed with 7 mL of glycogen (50 mg/mL) to enhance precipitation. Samples were transferred to an miRNeasy mini column, and RNA was precipitated with 750 mL of ethanol followed by washing with RPE and RWT buffer. RNA was eluted in 30 mL of nuclease-free water and stored at 280°C until further analysis.
Starting from total RNA samples, we synthesized complementary DNA using the Universal cDNA Synthesis Kit II (Exiqon). We chose reaction conditions according to recommendations of the manufacturer. The protocol was modified in that 4 mL of total RNA was used per 10 mL reverse transcription (RT) reaction. To monitor RT efficiency and the presence of impurities with inhibitory activity, a synthetic RNA spike-in (cel-miR-39-3p) was added to the RT reaction. Polymerase chain reaction amplification was performed in a 384-well plate format using custom Pick-&-Mix plates (Exiqon) in a Roche LC480 II instrument (Roche, Mannheim, Germany) and EXiLENT SYBR Green Master Mix (Exiqon) with the following settings: 95°C for 10 minutes, 45 cycles of 95°C for 10 seconds and 60°C for 60 seconds, followed by melting curve analysis. To calculate the cycle of quantification (Cq)-values, the second derivative method was used. Cq-values were normalized to the mean Cq-value in each sample (global mean normalization) by subtracting the individual miRNA Cq-value from the Cq average calculated for that sample. Experimental design, platform description, and raw as well as normalized data were submitted to the Gene Expression Omnibus according to the Minimum Information for Publication of Quantitative Real-Time PCR Experiments guidelines (accession number GSE103473).
Statistical analysis
We used ClustVis to perform exploratory data analysis (30) . Principal component analysis and hierarchical clustering analyses were performed using the default settings (i.e., singular value decomposition with imputation, correlation as the distance metric, and average distance for clustering). Groupwise differential expression analysis based on global mean normalized D Cq-values under the assumption of normal distribution was performed, which was assessed visually using two-sided t tests. Receiver operator characteristic analysis was performed to evaluate the power of selected circulating miRNAs to distinguish WNT1 MP subjects from MN subjects. Receiver operator characteristic analysis was performed using MedCalc Statistical Software version 18 (Ostend, Belgium; http://www.medcalc.org; 2018) to compute area-under-thecurve values.
Study approval
All genetic and clinical studies were approved by the Research Ethics Board of Helsinki University Hospital. All subjects gave written informed consent before participation in the study.
Results
Clinical and biochemical characteristics
We recruited study subjects from two families with autosomal dominant WNT1 osteoporosis. On the basis of pedigree analysis, we selected 12 mutation-positive and 12 mutation-negative (hereafter MP and MN, respectively) family members for the analyses ( Fig. 1 ; Table 1 ), aiming at comparable age and sex distribution in the MP and MN groups. The MP cohort thus represented approximately half of all Finnish subjects identified with a WNT1 mutation. The selected subjects were negative for all four (22 subjects) or for three (two subjects) of the following exclusion criteria: (1) a fracture in the past 12 months, (2) use of bisphosphonate or other osteoporosis medication in the past 12 months, (3) hypothyroidism, and (4) use of aspirin or other possible confounding medications.
The MP group comprised seven females and five males (median age, 39 years; range, 11 to 76 years), and the MN group comprised five females and seven males (median age, 34.5 years; range 9 to 59 years) ( Fig. 1 ; Table 1 ). The MP subjects had dual-energy X-ray absorptiometrymeasured BMD values ranging from normal to osteoporosis (z score less than 22.5) and a history of multiple fractures and other skeletal manifestations, but none had had fractures or orthopedic surgeries in the past 12 months and none had other confounding illnesses (Supplemental Table 1 ). Regarding medications, three MP subjects had received osteoporosis medication .12 months before the study, whereas one subject (MP-4) had received the most recent dose of low-dose pamidronate treatment (1 mg/kg once every 4 months) 3 months before the study. Another male subject (MP-13) used aspirin. Serum 25-hydroxy-vitamin D concentration in the MP group was slightly higher than that in the MN group (90 nmol/L vs 68 nmol/L), as the MP subjects also received, on average, higher vitamin D supplementation (53 mg/d vs 9 mg/d).
Other parameters of calcium homeostasis and bone turnover, including 1,25-dihydroxyvitamin D, parathyroid hormone, type 1 cross-linked C-telopeptide, and intact fibroblast growth factor 23, were similar in the MP and MN groups (Supplemental Fig. 1 ; Table 1 ). In the MN group, seven of 12 subjects had previously been assessed with dualenergy X-ray absorptiometry or spinal magnetic resonance imaging with no signs of osteoporosis or spinal compression fractures (Supplemental Table 1 ) (21, 31) .
Quality control of miRNA quantitation
We used a previously described analytical workflow to screen 192 distinct miRNA species and controls in the 12 MP and 12 MN subjects (14) . Spike-in controls added before RNA extraction, RT, and quantitative polymerase chain reaction amplification were used to assess the technical variance of the workflow (Supplemental Fig. 2 ) and identify potential outliers. We observed low technical variance in spike-in controls (11% to 23% coefficient of variation). To exclude a potential bias in our data due to hemolysis, we calculated a hemolysis index on the basis of the ratio of miR-451a/miR-23a-3p (32, 33) . None of the samples exhibited a ratio .7, which would indicate hemolysis. The overall sensitivity of the analysis was very good. Missing values for low abundant miRNAs were observed in only six of the 24 total samples. Of the 192 analyzed miRNAs, the maximum number of missing miRNA values observed in any sample was two (Supplemental Data).
Exploratory data analysis
We performed unsupervised exploratory data analyses in the form of principal component analysis and hierarchical clustering to assess the overall impact of the WNT1 mutation on circulating miRNA patterns in MP subjects compared with MN subjects. Using data from the 50 most variable miRNAs (sorted by coefficient of variation %), we observed that overall circulating miRNA levels were not significantly determined by WNT1 mutation status, sex, or subfamily division ( Fig. 2A; Supplemental Fig. 3 ). However, group-wise comparison of circulating miRNA levels between MP and MN subjects revealed a balanced number of up-and downregulated miRNAs (Fig. 2B) . In total, after application of a low-stringent P value cutoff of ,0.1 to reduce the number of false-negatives (Table 2) , this screening identified 16 putative miRNAs that together enabled good discrimination between MP and MN subjects (Fig. 3A) .
Two of these miRNAs (miR-18a-3p and miR-223-3p) were significantly upregulated (P , 0.043), whereas five miRNAs (miR-22-3p, miR-34a-5p, miR-423-5p, miR-423-3p, and miR-143-5p) were significantly downregulated (P , 0.045) in MP subjects (Fig. 3B-3I ). Two miRNAs, miR-22-3p and miR-34a-5p, exhibited good classification performance with area-under-the-curve Figure 1 . Pedigrees of the families with a heterozygous p.C218G WNT1 mutation. Squares represent males, and circles represent females. Black symbols represent mutation-positive family members, white symbols represent mutation-negative family members, and gray symbols represent mutation-negative healthy controls participating in this study. Slashes represent deceased family members. The pedigree has been altered to ensure anonymity.
values reaching 0.896 and 0.868, respectively. Correlation between the significantly regulated miRNAs was observed at varying moderate degrees, suggesting that some single miRNAs might contain information derived from different phenotypic characteristics caused by the WNT1 mutation (Supplemental Table 2 ). Ongoing lowdose bisphosphonate treatment in one MP female (MP-4) had no effect on miRNA values (Supplemental Fig. 4) In silico prediction of miRNA targets
We used Targetscan release 7.1 to identify predicted miRNA binding sites in the 3 0 UTR of the human WNT1 gene (34) . The tool reported putative binding sites for three miRNAs-miR-22-3p, miR-34a-5p, and miR-31-5p-which we found to be downregulated in the serum of MP subjects. For miR-34a-5p and miR-22-3p, binding to and regulation of WNT1 has been experimentally validated (35) (36) (37) (38) . For miR-31-5p, experimental confirmation of a direct interaction with WNT1 has not been reported, although its interference with the WNT signaling ligand frizzled 3 has been observed (9) .
Discussion
This study reports on miRNA profiles in subjects with a monogenic bone disease due to defective WNT signaling. All of our MP subjects harbored the heterozygous missense mutation p.C218G in WNT1, which was previously shown to lead to decreased WNT signaling, low bone formation, low BMD, and fractures (21, 22) , whereas the MN subjects had normal BMD and no fractures (21, 31) . We screened a custom-designed panel of 192 miRNAs and compared the results from 12 MP subjects with those from 12 MN subjects. Our results show that a unique profile of eight miRNAs differentiated between MP and MN subjects and that three of these miRNAs, miR-22-3p, miR-34a-5p, and miR-31-5p, were downregulated in the serum of MP subjects (P = 0.001, P = 0.003, and P = 0.053, respectively). All three miRNAs are known inhibitors of WNT signaling, and miR-22-3p and miR-34a-5p have been shown to target WNT1 specifically (35) (36) (37) (38) . To the best of our knowledge, no previously published data have reported a direct association between miR-31-5p and WNT1. Recent research found that circulating miRNAs are promising new markers in various diseases, including malignancies, as many conventional biomarkers have shown limitations in diagnostics and in evaluating treatment outcomes (29) . Regarding bone health and disease, current conventional metabolic bone markers are inadequate in reflecting bone health status, predicting future fracture risk, or monitoring treatment efficacy (12, 39, 40) . Circulating miRNAs show promise as future bone markers, as specific miRNAs that discriminate [e.g., patients with manifest osteoporosis (14, 16, 41) ] have also influenced bone metabolism in vitro (1, 13, 14, 24, (42) (43) (44) and in vivo (16, 41) . This suggests that circulating miRNAbased biomarkers might have causal links to the disease phenotype, as miRNAs packaged in extracellular vesicles or in protein particles can be taken up by recipient cells in an auto-, para-, or even endocrine manner (45) .
Of the eight miRNAs identified in our study as discriminating between MP and MN subjects, seven have reportedly influenced bone metabolism (Table 3) . Interestingly, three of the downregulated miRNAs in MP subjects were confirmed or predicted to directly target WNT signaling and specifically WNT1 messenger RNA. One of these, miR-22-3p, negatively regulates osteogenesis and osteoblastogenesis through WNT signaling by targeting the coding region and suppressing the expression of b-catenin, which inhibits formation of calcium nodules during osteoblast differentiation (10). miR-22-3p also targets and decreases the levels of Tcf7 and Ep300, key transcriptional proteins for target gene expression in the WNT pathway (57) . Furthermore, the 3 0 UTR of WNT1 contains a binding site for miR-22-3p, and miR-22-3p directly targets WNT1 (35). Secondly, miR-34a-5p interacts with WNT pathway components (58) and also directly with WNT1 to regulate its messenger RNA expression and posttranscriptional translation (36) (37) (38) . Lastly, Weilner et al. (9) showed that miR-31-5p interacts with the WNT pathway component frizzled-3 and suppresses WNT signaling, whereas Xi et al. (59) showed that miR-31-5p targets WNT pathway antagonists Dkk-1 and DACT3 in lung cancer cells. However, unlike with miR-22-3p and miR-34a-5p, there are no reports of miR-31-5p directly targeting WNT1.
Intriguingly, our findings suggest that decreased WNT signaling due to mutated WNT1 leads to downregulation of miRNAs that exhibit suppressive action on the WNT pathway. This could be regarded as an attempt to normalize WNT signaling in a situation where WNT1-related WNT signaling is impaired. The molecular and genetic feedback mechanisms governing balanced bone metabolism, including gene regulation by miRNAs, are inadequately understood. To the best of our knowledge, miR-423-3p, which was significantly downregulated in our MP subjects, has not been previously linked to bone metabolism or WNT signaling. Wang et al. (60) previously reported that miR-423-3p expression changed with age in the microvesicles of mouse bone marrow mesenchymal stem cells, but no evidence for its effect on osteogenesis was shown. Also, other studies reported that miR-423-3p was linked to myocardial tissue and heart diseases (61, 62), but no specific heart phenotype or increased prevalence of myocardial disease was observed in our cohort or in other WNT1 MP subjects (21, 22) . Therefore, the suggestion of an association between miR-423-3p and the WNT pathway is notable.
Prior or ongoing osteoporosis medication use could potentially alter an individual's miRNA expression, although the mechanisms and exact consequences are still unclear (63) . Altogether, our cohort included three subjects with previous osteoporosis medication use and one subject with ongoing low-dose pamidronate treatment at the time of the study. A separate analysis showed that bisphosphonate treatment had no effect on the expression of the eight specific miRNAs in our cohort; therefore, the observed differences between MP and MN groups are likely not related to the patients' medical therapy. We previously showed that conventional bisphosphonates had little to no effect on BMD status in WNT1 MP patients (22) .
The therapeutic potential in miRNAs has been contemplated and experimentally tested in previous studies. Krzeszinski et al. (46) were able to attenuate postmenopausal osteoporosis in ovariectomized mice with the administration of systemic miR-34; Wang et al. (64) showed the anabolic potential of anti-miR-214 in stimulating bone formation in mice; and Wang et al. (42) demonstrated protection against glucocorticoid-induced bone loss with miR-29a in rats. In a wider context, miRNAs are used clinically in cancer treatment as replacement therapies, to sensitize tumors to chemotherapy, and to treat drug-resistant malignancies (65) . Whether the miRNAs upregulated or downregulated in our study could have therapeutic potential-as drug targets or exogenously administered medications-in WNT1 or other forms of osteoporosis should be explored in future experimental settings.
Our study provides data on miRNA expression levels in WNT-related bone disease. The study could have been strengthened by larger cohort sizes and with only subjects with no confounding factors, such as use of osteoporosis medication. However, we did exclude subjects with recent fractures and showed that subjects with previous or ongoing osteoporosis medication use did not differ from the others in miRNA patterns. Further, to minimize the effect of other confounding genetic factors, we recruited MN subjects from the same families as MP subjects. We also considered the premenopausal and postmenopausal status of female subjects as a possible confounding factor. However, the two cohorts were very similar in age and sex distribution, alleviating possible bias. Furthermore, there was no overlap with the miRNAs reported in this study and those previously reported to have alternative expression as a result of changes in estradiol concentration in Finnish subjects (65, 66) .
The small sample size may have prevented us from observing some important differences between the groups, leading to a high false-negative rate. We tried to account for this by allowing relatively high type-I error (P , 0.1) for initial selection. An independent cohort of WNT1 MP/MN subjects would be required to validate miR-22, miR-34a, and miR-31 findings. However, because of the scarcity of subjects with confirmed WNT1 or other WNT pathwayrelated osteoporosis, such a study was not possible. Despite these limitations and acknowledging the worldwide rarity of WNT1 osteoporosis and WNT1 mutation-positive individuals and the overall scarcity of miRNA data in monogenic bone disorders, we consider our study's setting and findings valid and valuable.
We concluded that a unique miRNA profile was observed in WNT1 mutation-positive individuals compared (8, 9, 55, 56) with healthy individuals. These observations provide valuable information about the molecular pathways involved in WNT1 osteoporosis and the effect of aberrant WNT signaling on miRNA expression. Our data also support an association between WNT1 and miR-31-5p and miR-423-3p expression. The specific miRNAs highlighted in this study could serve as circulating metabolic bone markers in WNT1 osteoporosis to evaluate bone health, fracture healing, and treatment efficacy in affected individuals. Future studies are encouraged to further explore these specific miRNAs in other WNT pathway-related skeletal diseases, their response to antiosteoporosis treatment, and their potential utilization in the development of osteoporosis treatment.
